NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo

NG25, an inhibitor of transforming growth factor‑β‑activated kinase 1, ameliorates neuronal apoptosis in neonatal hypoxic‑ischemic rats

(2017) Hua Wang et al.   Molecular Medicine Reports

BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB

(2016) Jipei Du et al.   CANCER LETTERS

TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells

(2016) Zhenyu Wang et al.   Scientific Reports

Ubiquitin specific protease 4 positively regulates the WNT/β-catenin signaling in colorectal cancer

(2015) Sun-Il Yun et al.   Molecular Oncology

Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells

(2015) Jennifer E. Hrabe et al.   Redox Biology

TAK1 control of cell death

(2014) S R Mihaly et al.   CELL DEATH AND DIFFERENTIATION

KRAS mutations: Analytical considerations

(2014) Marta Herreros-Villanueva et al.   CLINICA CHIMICA ACTA

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)

(2014) Li Tan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification byKRASMutations in Advanced Colorectal Cancer

(2013) Issa J. Dahabreh et al.   ANNALS OF INTERNAL MEDICINE

TAK1 Inhibition Promotes Apoptosis in KRAS-Dependent Colon Cancers

(2012) Anurag Singh et al.   CELL

Retraction for Zhong et al., GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38

(2012)   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

(2011) Gordon Hutchins et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation

(2008) Eugene Varfolomeev et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Diverse functions within the IAP family

(2008) J. M. Rumble et al.   JOURNAL OF CELL SCIENCE

Noncanonical NF-κB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK

(2008) Brian J Zarnegar et al.   NATURE IMMUNOLOGY

Both cIAP1 and cIAP2 regulate TNF -mediated NF- B activation

(2008) D. J. Mahoney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA